Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), affects as many as 600 000 Americans, killing more than 100 000 people each year and resulting in significant morbidity and mortality.
1 Trauma is known to be one of the strongest risk factors for VTE. A prospective study
2 reported rates of DVT as high as 58% among those who experience severe trauma without thromboprophylaxis, although other registry-based studies
3,4 have reported lower rates. Guidelines recommend VTE prophylaxis with low-molecular-weight heparin in trauma.
5,6